Cargando…
Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
BACKGROUND: Osteosarcoma commonly develops during childhood and adolescence. Only one-third of osteosarcoma patients have been clinically detected over the age of 40 years, and the survivorship of those patients is quite dismal. Apatinib, a novel multitarget angiogenesis inhibitor, has shown a short...
Autores principales: | Gong, Taojun, Huang, Qi, Tang, Fan, Wang, Yitian, Li, Zhuangzhuang, Luo, Yi, Min, Li, Zhou, Yong, Tu, Chongqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664205/ https://www.ncbi.nlm.nih.gov/pubmed/36387068 http://dx.doi.org/10.3389/fonc.2022.1031787 |
Ejemplares similares
-
Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023) -
Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022) -
A case report of apatinib in treating osteosarcoma with pulmonary metastases
por: Zhou, Yong, et al.
Publicado: (2017) -
The efficacy and safety of apatinib in Ewing’s sarcoma: a retrospective analysis in one institution
por: Wang, Yitian, et al.
Publicado: (2018) -
Multiple Pulmonary Metastases of Recurrent Giant Cell Tumor of Bone with Expression of VEGFR-2 Successfully Controlled by Denosumab and Apatinib: A Case Report and Literature Review
por: Gong, Taojun, et al.
Publicado: (2021)